Video

Dr. Inman Discusses the Biology of Bladder Cancer

Author(s):

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the biology of bladder cancer.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the biology of bladder cancer.

Bladder cancer is being better understood with the utilization of genome sequencing and RNA sequencing, both of which have allowed for this disease to be categorized into several different molecular subtypes.

Tests to check for these subtypes will become important in the future, Inman says, as it will help guide treatment for patients.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD